ABT-436 explained

ABT-436 is an orally active, highly selective vasopressin V_1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued.^{[1] [2] [3]} It reached phase II clinical trials prior to the discontinuation of its development.

See also

• Balovaptan
• Nelivaptan
• SRX-246
• TS-121

Notes and References

1. Web site: ABT 436 . AdisInsight . Springer Nature Switzerland AG .
2. Wernet W, Hornberger WB, Unger LV, Meyer AH, Netz PA, Oost T, Hillen H, Fogdell-Hahn A, Schoemaker H, Backfish G, Beyerbach A . 6 . In vitro characterization of the selective vasopressin V1b receptor antagonists ABT-436 and ABT-558. . Proceedings of Society for Neuroscience . Washington DC, USA . Abstract 560 . 2008 .
3. Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, Strain EC, Dunn KE, Kampman K, Mahoney E, Ciraulo DA, Sickles-Colaneri L, Ait-Daoud N, Johnson BA, Ransom J, Scott C, Koob GF, Litten RZ . 6 . A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence . Neuropsychopharmacology . 42 . 5 . 1012–1023 . April 2017 . 27658483 . 10.1038/npp.2016.214 . 5506792 . free .